Multidisciplinary medical oncological treatment of colorectal cancer (CRC);A colorectalis carcinoma multidiszciplináris szemléletu belgyógyászationkológiai kezelése

Lege Artis Medicinae

Volumn 11, Issue 2, 2001, Pages 118-129

  Lang I ^a  

^a Kemoter B Belgyogy Onkol Osztaly   (Hungary)

Author keywords

Chemotherapy; Colorectal cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; RALTITREXED;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; METASTASIS; RECTUM CANCER; REVIEW; TREATMENT PLANNING;

EID: 0035075121     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil
2. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
3. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report
4. Post-operative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP Protocol C-01
5. The benefit of leucovorin-modulated fluorouracil as prosperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03
6. The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LV-LEV) in patients with Dukes B and C carcinoma of the colon: First report of NSABP C-04
7. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
8. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
9. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III. Trial
10. Event free and overall survival is increased by FUFA in resected B colon cancer: A pooled analysis of five randomised trials
11. Efficacys of adjuvant fluorouracil and folinic acid in B2 colon cancer?
12. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four national surgical adjuvant breast and bowel project adjuvant studies (C-01, C-02, C-03 and C-04)
13. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven year outcome of a multicenter randomized trial
14. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: Preliminary result of National Surgical Adjuvant Breast an Bowel Project Protocol C-02
15. Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer
16. Portal vein chemotherapy for colorectal cancer: A meta-analysis of 4000 patients in 10 studies
17. Prolongation of the disease-free interval in surgically resected rectal cancer
18. Survival after post-operative combination treatment of rectal cancer
19. Effective surgical adjuvant therapy for high-risk rectal carcinoma
20. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery
21. Improved survival with preoperative radiotherapy in resectable rectal cancer
22. Incidence and detection of occult hepatic metastases in colorectal carcinoma
23. Natural history of patients with untreated liver metastases from colorectal cancer
24. Weekly irinolecan (CPT-11), leucovorin and fluorouracil is superior to daily × 5 leucovorin + 5-FU in patients with previously untreated metastatic colorectal cancer
25. A randomized phase III trial comparing irinotecan + 5-FU + folinic acid to the same schedule of 5-FU + folinic acid in patients with metastatic colorectal cancer as front line chemotherapy
26. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer
27. A chronopharmacologic phase II. clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump
28. A multicenter phase 5-fluorouracil II. Trial of intensified chronotherapy with oxaliplatin (LOHP), 5 fluorouracil (5-FU) and folinic acid (FA) in patients (PTS) with previously untreated metastatic colorectal cancer (MCC)
29. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial
30. Randomised multicentre trial of chronotherapy with oxaliplatin fluorouracil, and folinic acid in metastatic colorectal cancer
31. Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC)
32. A randomized trial of leucovorin (LV) and 5-fluorouracil (5-FU) with or without oxaliplatin in advanced colorectal cancer (CRC)
33. Analysis of prognostic factors of overall survival (OS) in the randomized trial of bimonthly leucovorin and 5-fluorouracil regimen (LV5FU2) with or without oxaliplatin (OXA) in advanced colorectal cancer (ACC)
34. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer
35. Intra-arterial floxuridine versus systemic fluorouracil for hepatic metastases from colorectal cancer
36. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer
37. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy
38. Reduction of nonresectable liver metastasis from colorectal cancer after oxalipatin chemotheraphy
39. Long-term survival of patients (PTS) with unresectable colorectal liver metastasis following infusional chemotheraphy with 5-fluorouracil, folinic acid, oxaliplatin and surgery
40. Hepatic arterial chemotherapy in metastatic colorectal patients
41. Weekly therapy with folinic acid (FA) and high-dose fluorouracil (5-FU) 24 hour infusion in pre-treated patients with metastatic colorectal carcinoma
42. High-dose 5-fluorouracil (5FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5FU treatment: Results of a phase II. Study
43. Protracted venous infusion of 5-fluorouracil and alfa-interferon in advanced and refractory colorectal cancer
44. Low-dose 5-FU continuous infusion (FuCl) in advanced colorectal cancer (ACC): Clinical evidence for reversal of acquired-intrinsic resistance to 5-FU or 5-FU folonic acid (FuFo)
45. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil fallure in patients with metastatic colorectal cancer
46. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer
47. Irinotecan in second-line treatment of metastatic colorectal cancer: Improved survival and cost-effect compared with infusional 5-FU
48. Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure